Trulieve Expands with Alien Labs and Connected Brands in Florida and Texas

TALLAHASSEE, Fla., Sept. 28, 2026 /CourierPR/ -- Trulieve Cannabis Corp., a leading medical cannabis company in the U.S., has announced a significant expansion of its product portfolio through a master licensing agreement with Connected. This deal will allow Trulieve to cultivate, manufacture, and commercialize Alien Labs and Connected branded cannabis products in Florida and Texas, maintaining the high quality standards and proprietary know-how of the brands.

Since 2022, Trulieve has been an exclusive provider of Alien Labs and Connected premium cannabis products in Florida, delighting customers with unique high-quality strains. The new agreement will enable Trulieve to introduce these products to patients in Texas, pending final licensure and regulatory approvals. The company plans to expand its premium product portfolio in Florida with new categories and form factors, further solidifying its leading market position.

Trulieve, with established medical marijuana operations in Florida, Georgia, Pennsylvania, and West Virginia, is poised for accelerated growth through its hub strategy. The company's platform has provided Florida patients with access to Alien Labs and Connected genetics developed through Connected's proprietary breeding program. The agreement with Connected also provides Trulieve with the opportunity to negotiate licensing rights in additional expansion markets, beyond Florida and Texas.

Forward-looking statements in this news release are subject to known and unknown risks, uncertainties, and other factors that may cause actual events, results, performance, or achievements of the company to be materially different from those contained in the forward-looking statements. Risks and uncertainties include, without limitation, the risks and factors discussed under the heading "Risk Factors" in Trulieve's Annual Report on Form 10-K for the year ended December 31, 2025, and in its periodic reports subsequently filed with the United States Securities and Exchange Commission and in the company's filings on SEDAR+ at www.sedarplus.ca. There can be no assurance that any forward-looking statements herein will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements.